Roivant Sciences Ltd. - Common Shares, par value $0.0000000341740141 per share (ROIV)

Historical Holders from Q4 2021 to Q3 2025

Symbol
ROIV on Nasdaq
Type / Class
Equity / Common Shares, par value $0.0000000341740141 per share
Shares outstanding
695M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
502M
Holdings value
$7.59B
% of all portfolios
0.016%
Grand Portfolio weight change
0%
Number of holders
331
Number of buys
181
Number of sells
-153
Average Value change %
0%
Average buys %
+0.004%
Average sells %
-0.005%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Roivant Sciences Ltd. - Common Shares, par value $0.0000000341740141 per share (ROIV)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Ramaswamy Vivek 11.63% +3.91% $913M $11.00 83M +0% Ramaswamy Vivek 31 Mar 2025
FMR LLC 8.2% $603M 55.5M FMR LLC 30 Jun 2025
SB INVESTMENT ADVISERS (UK) LTD 5.8% -30% $610M -$329M 40.3M -35% SB Investment Advisers (UK) Limited 30 Sep 2025
MORGAN STANLEY 5.5% $409M 37.6M Morgan Stanley 30 Jun 2025
QVT Financial LP 4.3% -54.7% $319M -$395M 29.4M -55.3% QVT Financial LP 30 Jun 2025
VIKING GLOBAL INVESTORS LP 3.4% -32.4% $357M -$161M 23.6M -31.1% VIKING GLOBAL INVESTORS LP 30 Sep 2025

Institutional Holders of Roivant Sciences Ltd. - Common Shares, par value $0.0000000341740141 per share (ROIV)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 502M $7.59B -$163M $15.13 331
2025 Q2 515M $5.8B -$419M $11.27 337
2025 Q1 553M $5.58B -$111M $10.09 310
2024 Q4 562M $6.65B -$86.4M $11.83 312
2024 Q3 569M $6.57B +$224M $11.54 291
2024 Q2 546M $5.77B +$152M $10.57 293
2024 Q1 532M $5.6B -$166M $10.54 258
2023 Q4 542M $6.08B -$172M $11.23 223
2023 Q3 546M $6.38B +$538M $11.68 205
2023 Q2 497M $5.01B +$398M $10.08 178
2023 Q1 459M $3.39B +$349M $7.38 144
2022 Q4 412M $3.29B +$292M $7.99 107
2022 Q3 371M $1.19B +$30.8M $3.22 75
2022 Q2 360M $1.47B +$45.6M $4.07 71
2022 Q1 349M $1.72B +$48.2M $4.94 50
2021 Q4 339M $3.42B +$3.37B $10.08 40